Advertisement
-
1
Ghannoum MA, Hajjeh RA, Scher R, et al: A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns [abstract]. .J Am Acad Dermatol 43::641. ,2000. .
-
2
Gupta AK: Types of onychomycosis. .Cutis 68::4. ,2001. .
-
3
Gupta AK, Konnikov N, MacDonald P, et al: Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. .Br J Dermatol 139::665. ,1998. .
-
4
Gupta AK, Fleckman P, Baran R: Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. .J Am Acad Dermatol 43::S70. ,2000. .
-
5
Boyko WL, Doyle JJ, Ryu S, et al: Onychomycosis and its impact on secondary infection development in the diabetic population. .Value Health 2::199. ,1999. .
-
6
Doyle JJ, Boyko W, Ryu S, et al: Onychomycosis among diabetic patients: prevalence and impact of nonfungal foot infections [abstract]. .Diabetes 49::195. ,2000. .
-
7
Aye M, Masson EA: Dermatological care of the diabetic foot. .Am J Clin Dermatol 3::463. ,2002. .
-
8
Levy LA: Epidemiology of onychomycosis in special-risk populations. .JAPMA 87::546. ,1997. .
-
9
Tom CM, Kane MP: Management of toenail onychomycosis. .Am J Health Syst Pharm 56::865. ,1999. .
-
10
Robbins JM: Treatment of onychomycosis in the diabetic patient population. .J Diabetes Complications 17::98. ,2003. .
-
11
Katz HI: Drug interactions of the newer oral antifungal agents. .Br J Dermatol 141::26. ,1999. .
-
12
Katz HI, Gupta AK: Oral antifungal drug interactions. .Dermatol Clin 15::535. ,1997. .
-
13
Breckenridge A: Clinical significance of interactions with antifungal agents. .Br J Dermatol 126::19. ,1992. .
-
14
Gupta AK, Einarson TR, Summerbell RC, et al: An overview of topical antifungal therapy in dermatomycoses: a North American perspective. .Drugs 55::645. ,1998. .
-
15
Anonymous: Ciclopirox (Penlac) nail lacquer for onychomycosis. .Med Lett Drugs Ther 42::51. ,2000. .
-
16
Ceschin-Roques CG, Hanel H, Pruja-Bougaret SM, et al: Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin. .Skin Pharmacol 4::89. ,1991. .
-
17
Seebacher C, Nietsch K-H, Ulbricht HM: A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. .Cutis 68::17. ,2001. .
-
18
Gupta AK: Ciclopirox nail lacquer topical solution 8%. .Skin Ther Lett 6::1. ,2000. .
-
19
Gupta AK, Baran R: Ciclopirox nail lacquer solution 8% in the 21st century. .J Am Acad Dermatol 43::S96. ,2000. .
-
20
Gupta AK, Malkin KF: Ciclopirox nail lacquer and podiatric practice. .JAPMA 90::502. ,2000. .
-
21
Penlac Nail Lacquer (ciclopirox) Topical Solution 8% [package insert], Dermik Laboratories, Berwyn, PA, January. 2005. .
-
22
Gupta AK, Joseph WS: Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. .JAPMA 90::495. ,2000. .
-
23
Armstrong DG, Lavery LA, Harkless LB: Who is at risk for diabetic foot ulceration? Clin Podiatr Med Surg 15: 11. ,1998. .
-
24
Rich P, Hare A: Onychomycosis in a special patient population: focus on the diabetic. .Int J Dermatol 38: (suppl 2):17. ,1999. .
-
25
Rich P: Special patient populations: onychomycosis in the diabetic patient. .J Am Acad Dermatol 35::S10. ,1996. .
-
26
Damanhouri Z, Gumbleton M, Nicholls PJ, et al: In-vivo effects of itraconazole on hepatic mixed-function oxidase. .J Antimicrob Chemother 21::187. ,1988. .
-
27
Gumbleton M, Houston WA, Nicholls PJ, et al: Tolbutamide pharmacokinetics, in the presence of itraconazole, in the rat. .J Pharm Pharmacol 39: (suppl 1):150. ,1987. .
-
28
Sporanox (itraconazole) [package insert], Janssen Pharmaceutica Products LP, Titusville, NJ, January. 2004. .
-
29
Lamisil (terbinafine hydrochloride) Tablets [package insert], Novartis Pharmaceuticals Corp, East Hanover, NJ, June. 2006. .
-
30
Kellner HM, Arnold C, Chirst OE, et al: Pharmacokinetics and biotransformation of the antimycotic drug ciclopirox olamine in animals and man after topical and systemic administration (in German). .Arzneimittelforschung 31::1337. ,1981. .
-
31
Bohn M, Kraemer KT: Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. .J Am Acad Dermatol 43::S57. ,2000. .
-
32
Markus A: “Hydroxy Pyridones Outstanding Biological Properties,” in Hydroxy Pyridones as Antifungal Agents with Special Emphasis on Onychomycosis, ed by S Shuster, p 1, Springer-Verlag, Berlin. ,1999. .
-
33
Korting HC, Grundmann-Kollman M: The hydroxypyridones: a class of antimycotics of its own. .Mycoses 40::243. ,1997. .
-
34
Ulbricht H, Worz K: Therapy of onychomycosis due to moulds with ciclopirox lacquer. .Mycoses 37: (suppl 1):97. ,1994. .
-
35
Rollman O, Johansson S: Hendersonula toruloidea infection: successful response of onychomycosis to nail avulsion and topical ciclopiroxolamine. .Acta Derm Venereol 67::506. ,1987. .
-
36
Yu B, Zhou G, Wang B, et al: A clinical and laboratory study of ciclopirox olamine (8% Batrafen) in the treatment of onychomycosis. .Chin Med Sci J 6::166. ,1991. .
Ciclopirox 8% Nail Lacquer Topical Solution for the Treatment of Onychomycosis in Patients with Diabetes
A Multicenter, Open-Label Study
Search for other papers by Marc A. Brenner in
Current site
Google Scholar
PubMed
Search for other papers by Lawrence B. Harkless in
Current site
Google Scholar
PubMed
Search for other papers by Robert W. Mendicino in
Current site
Google Scholar
PubMed
Search for other papers by Jeffrey C. Page in
Current site
Google Scholar
PubMed
Background: An open-label, noncomparative study was conducted to assess the safety and efficacy of ciclopirox 8% nail lacquer topical solution in patients with type 2 diabetes mellitus.
Methods: Forty-nine diabetic patients with distal subungual onychomycosis were treated once daily for 48 weeks with ciclopirox 8% nail lacquer, a topical nail solution approved for the treatment of patients with mild-to-moderate onychomycosis.
Results: Treatment resulted in clinical improvement in 63.4% of patients. Most patients (85.7%) had a mycologic outcome of improvement or cure, with 54.3% attaining mycologic cure. Consideration of mycologic and clinical outcomes generated a treatment outcome of improvement, success, or cure in 84.4% of patients. Moreover, patients experienced improvement in the diseased area of the nail (63.4%), nail surface (56.1%), nail color (48.8%), and nail thickness (65.9%). Ciclopirox 8% nail lacquer was safe, with treatment-related adverse events limited to infection in one patient, which resolved in 15 days; the patient completed the study. No treatment-related serious adverse events were observed.
Conclusion: Ciclopirox 8% nail lacquer is a safe and effective treatment for distal subungual onychomycosis in patients with type 2 diabetes mellitus receiving insulin or oral hypoglycemic therapy. (J Am Podiatr Med Assoc 97(3): 195–202, 2007)
